Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Miyazaki, Y.
Right arrow Articles by Defronzo, R. A
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician

Yoshinori Miyazaki

Elena De Filippis

Mandeep Bajaj

Estela Wajcberg

Leonard Glass

Curtis Triplitt

Eugenio Cersosimo

Lawrence J Mandarino

Ralph A Defronzo

University of Texas Health Science Center, Diabetes Division, Room 3.380S, 7703 Floyd Curl Drive, San Antonio, Texas, 78229-3900, USA, albarado{at}uthscsa.edu

Objective — To determine predictors of improved glycaemic control in patients with type 2 diabetes mellitus during rosiglitazone therapy using basic clinical parameters that are readily available in daily clinical practice. Research design and methods — Thirty-seven type 2 diabetic patients (men/women = 18/19; age = 54±2years; diabetes duration = 6±1 years; diet-/sulphonylurea-treated = 24/13) received a 75 g oral glucose tolerance test (OGTT) and determination of body fat before and after rosiglitazone (8 mg/day) for 12 weeks. Results — After rosiglitazone therapy, there were decreases in HbA1C (8.6±0.2 to 7.2±0.2%, p<0.0001), fasting plasma glucose (FPG) (10.6±0.3 to 8.0±0.3 mmol/L [191±6 to 145±6 mg/dL], p<0.0001), fasting plasma insulin (FPI) (108±6 to 84±6 pmol/L [18±1 to 14±µU/ml], p<0.05), fasting free fatty acids (FFA) (760±39 to 611±33 µEq/l, p<0.05), mean plasma glucose (PG) — OGTT (16.2±0.39 to 12.7±0.33 mmol/L [291±7 to 230±6 mg/dL], p<0.001), and mean FFA-OGTT (604±27 to 445±23 µEq/l, p<0.01) despite increases in body weight (85±2 to 88±2 kg, p<0.01) and % fat mass (37.9±2.0 to 39.5±1.9%, p<0.01). The insulinogenic index (IGI) during 0—120 minutes OGTT (IGI0-120) increased following rosiglitazone (0.19±0.03 to 0.30±0.05, p<0.01). Two different insulin sensitivity indices, calculated from PG and plasma insulin (PI) during OGTT, increased significantly: composite index of whole body insulin sensitivity (ISIcomposite): 2.3±0.3 to 3.4±0.4, p<0.05; oral glucose insulin sensitivity (OGIS): 248±5 to 294±6 ml/m2.min, p<0.001. Using clinical and laboratory variables obtained in daily clinical practice (age, gender, diabetes duration, sulphonylurea treatment, body mass index (BMI), % fat mass, fasting plasma insulin/C-peptide/FFA/lipids, IGI0-30, IGI0-120, and ISIcomposite or OGIS), stepwise regression analysis demonstrated that % fat mass (standard coefficient (S.C.) = —0.49, p=0.001) and OGIS (S.C. = 0.31, p=0.02) or ISIcomp (S.C. = 0.31, p=0.03) are significant predictors of the decrease in HbA1C after rosiglitazone (adjusted R2 =0.33, p=0.0004). Conclusions — Rosiglitazone improves insulin resistance and glycaemic control in type 2 diabetes. Obesity (more body fat mass) and reduced insulin sensitivity prior to treatment are the best predictors of glycaemic response to thiazolidinedione therapy in type 2 diabetes.

Key Words: type 2 diabetes mellitus • rosiglitazone • glycaemic control • insulin sensitivity.

References

  • DeFronzo RA Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetic genes. Diabetes Rev 1997;4:177269.
  • Stamler J., Vaccaro O., Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor-intervention trial. Diabetes Care 1993;16:434-44.[Abstract]
  • United Kingdom Prospective Diabetes Group: UK Prospective Diabetes Study 30: diabetic retinopathy at diagnosis of type 2 diabetes and associated risk factors. Arch Ophthalmol 1998;116:297-303.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study Group (UKPDS 33): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 year's therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.[Abstract]
  • Suter SL, Nolan JJ, Wallace P., Gumbiner B., Olefsky JM Metabolic effects of new oral hypoglycaemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.[Abstract]
  • Maggs DG, Buchanan TA, Burant CF et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus; a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:176-85.[Abstract/Free Full Text]
  • Inzucchi SE, Maggs D., Spollet GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72.[Abstract/Free Full Text]
  • Iwamoto Y., Kosaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. Effect of troglitazone: A new hypoglycaemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996;19:151-6.[Abstract]
  • Patel J., Anderson RJ, Rappaport EB Rosiglitazone monotherapy improves control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diab Obesity Metab 1999;1:165-72.[CrossRef]
  • Gillies PS, Dunn CJ Pioglitazone. Drugs 2000;60:333-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Simonson DC, Kourides IA, Feinglos M. et al. The Glipizide Gastrointestinal Therapeutic System Group: Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycaemic control and insulin secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997;20:597-606.[Abstract]
  • Bajaj M., DeFronzo RA Combination therapy in type 2 diabetes. In International Textbook of Diabetes Mellitus, edited by RA DeFronzo, E Ferrannini, H Keen, P Zimmet, 3rd edition, John Wiley & Sons, Chichester, England, pp.915-950, 2004.
  • DeFronzo RA, Goodman AM, and The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes. N Engl J Med 1995;333:541-9.[Abstract/Free Full Text]
  • Akazawa S., Sun F., Ito M., Kawasaki E., Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000;23: 1067-71.[Abstract/Free Full Text]
  • DeFronzo RA Lilly Lecture 1987: the triumvirate: ß-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37:667-87.[Web of Science][Medline] [Order article via Infotrieve]
  • Spiegelman BM PPAR-{gamma}:adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.[Abstract]
  • Lefebvre AM, Laville M., Vega N. et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998;47:98-103.[Abstract]
  • Hallakau S., Doare F., Foufelle F. et al. Pioglitazone induces in vivo adipocyte differentiation in obese Zucker fa/fa rats. Diabetes 1997;46: 1393-9.[Abstract]
  • Willson TM, Cobb JE, Cowan DJ et al. The structure-activity relationship between peroxisome proliferator-activated receptor {gamma} agonism and the antihyperglycaemic activity of thiazolidinediones. J Med Chem 1996;39: 665-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Auwerx J. PPAR{gamma} he ultimate thrifty gene. Diabetologia 1999;42:1033-49.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bays H., Mandarino L., DeFronzo R. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89:463-78.[Free Full Text]
  • Miyazaki Y., Mahankali A., Matsuda M. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91. 24. Mayerson AB, Hundal RS, Dufour S. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802. 25.Mori Y., Murakawa Y., Okada K. et al. Effects of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999;22:908-12.[Abstract]
  • Bajaj M., Suraamornkul S., Pratipanawatr T. et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes mellitus. Diabetes 2003;52:1364-70.[Abstract/Free Full Text]
  • Ye JM, Doyle PJ, Iglesias MA et al. Peroxisome proleferator-activated receptor (PPAR)-{alpha} activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats. Comparison with PPAR-{gamma} activation. Diabetes 2001;50:411-17.[Abstract/Free Full Text]
  • Jones TA, Sautter M., Van Gaal LF, Jones NP Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diab Obes Met 2003;5:163-70.[CrossRef]
  • DeFronzo RA Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.[Abstract/Free Full Text]
  • Simonson D., Ferrannini E., Bevilacqua S. et al. Mechanism of improvement in glucose metabolism following chronic glyburide therapy. Diabetes 1984;33:838-45.[Abstract]
  • Rossetti L., Giaccari A., DeFronzo RA Glucose toxicity. Diabetes Care-Reviews 1990;13:610-30.[CrossRef]
  • Matsuda M., DeFronzo RA Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycaemic insulin clamp. Diabetes Care 1999;22:1462-70.[Abstract/Free Full Text]
  • Mari A., Pacini G., Murphy E. et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001;24:539-48.[Abstract/Free Full Text]
  • Bonora E., Calcaterra F., Lombardi S. et al. Plasma glucose levels throughout the day and HbA1c relationships in type 2 diabetes. Diabetes Care 2001;24:2023-9.[Abstract/Free Full Text]
  • Adams M., Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor {gamma} have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997;100:3149-53.[Web of Science][Medline] [Order article via Infotrieve]
  • Okuno A., Tmemoto H., Tobe K. et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101:1354-61.[Web of Science][Medline] [Order article via Infotrieve]
  • Way JM, Harrington WW, Brown KK et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001;142:1269-77.[Abstract/Free Full Text]
  • Miyazaki Y., Glass L., Triplitt C. et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type 2 diabetic patients. Diabetologia 2001;44:2210-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Santomauro Atmg, Boden G., Silva Mer et al.Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999;48: 1836-41.[Abstract]
  • McGarry JD Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7-18. 41. Fruhbeck G., Gomez B -Ambrosi J., Muruzabal FJ, Burrell MA The adipocyte: a model for the integration of endocrine and metabolic signaling in energy metabolism. Am J Physiol 2001;280:E827-E847.[Web of Science]
  • Grag R., Kumbkarni Y., Aljada A. et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2003;36:430-5.
  • Natali A., Baldeweg S., Toschi E. et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27:1349-57.[Abstract/Free Full Text]
  • Chu J., Abbasi F., Lamendola C. et al. Improvements in vascular and inflammatory markers in rosiglitazone-treated insulin-resistant subjects are independent of changes in insulin sensitivity or glycaemic control. Diabetes 2003;52(suppl 1):A76.[CrossRef]
  • Miyazaki Y., Mahankali A., Matsuda M. et al. Improved glycaemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-19.[Abstract/Free Full Text]
  • Diamond MP, Thornton K., Connoly-Diamond M. et al. Reciprocal variation in insulin-mediated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Invest 1995;2: 708-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Prenki M., Corkey BE Are the beta cell signaling molecules malonyl CoA and cystosolic long-chain fatty acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 1996;45:273-83.[Abstract]
  • Itani SI, Ruderman NB, Schneider F., Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I{kappa}B-{alpha}. Diabetes 2002;51:2005-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 1, 28-35 (2005)
DOI: 10.1177/14746514050050010601
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Miyazaki, Y.
Right arrow Articles by Defronzo, R. A
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?